AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21316913 — intervention group
Group type: COMPARATOR
Intervention: Stryker Articular Surface Mounted (ASM) navigation
Number of subjects: 40
Study 19408465 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized training program
Number of subjects: 160
Study 19408465 — intervention group
Group type: COMPARATOR
Intervention: Blocked perceptual training
Number of subjects: 160
Study 19408465 — intervention group
Group type: COMPARATOR
Intervention: Reduced feedback (66%)
Number of subjects: 160
Study 16781604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761) 240 mg per day
Number of subjects: 22
Study 16781604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15046478 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of sustained release doxazosin for 7 days
Number of subjects: 40
Study 15046478 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of sustained release doxazosin after unsuccessful removal with 4 mg
Number of subjects: 40
Study 15046478 — intervention group
Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 40
Study 11078981 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH (20 microg/kg per day)
Number of subjects: 111
Study 11078981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 11078981 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH
Number of subjects: 111
Study 9107583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral stents used during and after SWL
Number of subjects: 0
Study 9107583 — intervention group
Group type: COMPARATOR
Intervention: Routine use of ureteral stents
Number of subjects: 0
Study 1550080 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion
Number of subjects: 160
Study 1550080 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU on days 2 to 6
Number of subjects: 160
Study 3158277 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg perorally, twice a day)
Number of subjects: 45
Study 3158277 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole (160‐800 mg perorally, twice a day)
Number of subjects: 45
Study 30282103 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of preeclampsia in one or more female relatives
Number of subjects: 9686
Study 30282103 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of preeclampsia in mother
Number of subjects: 9686
Study 30282103 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of preeclampsia in sister(s)
Number of subjects: 9686
Study 30282103 — intervention group
Group type: COMPARATOR
Intervention: No family history of preeclampsia
Number of subjects: 9686
Study 29370827 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO section appearing last in the survey
Number of subjects: 187
Study 29370827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical items appearing last in the survey
Number of subjects: 187
Study 29370827 — intervention group
Group type: COMPARATOR
Intervention: Clinical items appearing first in the survey
Number of subjects: 187
Study 28459708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg IV daily)
Number of subjects: 91
Study 28459708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 26107256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashtanga-based Yoga Therapy (AYT) program for 8 weeks
Number of subjects: 21
Study 26107256 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 21
Study 23933268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level school-based intervention to prevent secondhand smoke exposure
Number of subjects: 1734
Study 23933268 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 1734
Study 20568437 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) on Neiguan (PC 6) and Taichong (LR 3)
Number of subjects: 90
Study 20568437 — intervention group
Group type: COMPARATOR
Intervention: Paracervical block anesthesia (BA)
Number of subjects: 90
Study 20568437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TEAS and BA
Number of subjects: 90
Study 18806616 — intervention group
Group type: EXPERIMENTAL
Intervention: Added treatment group (doxazosin 1‐4 mg and atenolol when needed)
Number of subjects: 434
Study 18806616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 434
Study 18806616 — intervention group
Group type: EXPERIMENTAL
Intervention: Added treatment group
Number of subjects: 434
Study 16879463 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg pre-operatively, followed by gabapentin 2 x 600 mg on the day of operation and gabapentin 3 x 600 mg for the next 5 days, with rofecoxib 50 mg daily
Number of subjects: 49
Study 16879463 — intervention group
Group type: COMPARATOR
Intervention: Placebo with rofecoxib 50 mg daily
Number of subjects: 49
Study 12882846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (GI) diets
Number of subjects: 356
Study 12882846 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index (GI) diets
Number of subjects: 356
Study 10576173 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 0
Study 10576173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8704192 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 300 microgram/d
Number of subjects: 51
Study 8704192 — intervention group
Group type: COMPARATOR
Intervention: Control (0 microgram/d)
Number of subjects: 51
Study 8704192 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 51
Study 1680414 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol-containing peritoneal dialysis fluid (G-PDF)
Number of subjects: 8
Study 6960810 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole during remission maintenance therapy
Number of subjects: 37
Study 6960810 — intervention group
Group type: COMPARATOR
Intervention: No levamisole during remission maintenance therapy (control)
Number of subjects: 37
Study 6960810 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole during chemoimmunotherapy
Number of subjects: 37
Study 31670542 — intervention group
Group type: EXPERIMENTAL
Intervention: SB fading group
Number of subjects: 84
Study 31670542 — intervention group
Group type: COMPARATOR
Intervention: No instructions control group
Number of subjects: 84
Study 30311742 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 30311742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 30311742 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 1008
Study 30311742 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonanxious depression)
Number of subjects: 1008
Study 28673433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT)
Number of subjects: 46
Study 28673433 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 46
Study 25198416 — intervention group
Group type: EXPERIMENTAL
Intervention: Help condition (FGCs reflecting on a time when they helped family)
Number of subjects: 304
Study 25198416 — intervention group
Group type: COMPARATOR
Intervention: Control condition (FGCs not describing an example)
Number of subjects: 304
Study 25198416 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing-generation college students (CGCs)
Number of subjects: 304
Study 23360692 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of lutein daily
Number of subjects: 120
Study 23360692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20727555 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg, vitamin B6 40 mg, and cyanocobalamin 2 mg per day for 3 weeks
Number of subjects: 74
Study 20727555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 19930837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release paracetamol (acetaminophen) tablet formulation, three times daily dosing
Number of subjects: 0
Study 19930837 — intervention group
Group type: COMPARATOR
Intervention: Standard paracetamol tablets, four times daily dosing
Number of subjects: 0
Study 16865063 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga and meditation program
Number of subjects: 18
Study 16865063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga)
Number of subjects: 18
Study 12641522 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (rabeprazole 40 mg daily + amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg, and tinidazole 500 mg twice daily for 5 days)
Number of subjects: 1049
Study 12641522 — intervention group
Group type: COMPARATOR
Intervention: Standard 7-day therapy (rabeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1 g twice daily)
Number of subjects: 1049
Study 10708329 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal drug cues
Number of subjects: 24
Study 10708329 — intervention group
Group type: COMPARATOR
Intervention: Neutral cues
Number of subjects: 24
Study 10708329 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 24
Study 10708329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task paradigm (probe stimulus and imagery script)
Number of subjects: 24
Study 8244130 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 2 litres/minute
Number of subjects: 103
Study 8244130 — intervention group
Group type: COMPARATOR
Intervention: Air at 2 litres/minute (Control)
Number of subjects: 103
Study 3028663 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy with VP 16, ifosfamide, vindesine (VPIV), adriamycin, cisplatinum, vincristine (APO), and cyclophosphamide, methotrexate, CCNU (CMCC)
Number of subjects: 450
Study 3028663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum/VP 16 (PVP)
Number of subjects: 450
Study 3028663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide/VP 16 (IVP)
Number of subjects: 450
Study 3028663 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with ACO (adriamycin, cyclophosphamide, vincristine)
Number of subjects: 450
Study 30551334 — intervention group
Group type: EXPERIMENTAL
Intervention: Body psychotherapy
Number of subjects: 23
Study 30551334 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 23
Study 27030249 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 170
Study 27030249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 27030249 — intervention group
Group type: COMPARATOR
Intervention: Rasagiline 1 mg/day and Placebo
Number of subjects: 170
Study 25042018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower household per capita income (quartile 1, 2, 3)
Number of subjects: 670
Study 25042018 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 670
Study 25042018 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 670
Study 25042018 — intervention group
Group type: COMPARATOR
Intervention: Silent cerebral infarct
Number of subjects: 670
Study 25042018 — intervention group
Group type: COMPARATOR
Intervention: Painful episodes
Number of subjects: 670
Study 22419863 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK233705 20 μg + salmeterol 50 μg twice-daily
Number of subjects: 47
Study 22419863 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK233705 50 μg + salmeterol 50 μg twice-daily
Number of subjects: 47
Study 22419863 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg twice-daily
Number of subjects: 47
Study 22419863 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg once-daily
Number of subjects: 47
Study 22419863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 20413397 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 20323
Study 20413397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage (ICH)
Number of subjects: 20323
Study 20413397 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ICH major bleeding
Number of subjects: 20323
Study 20413397 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor bleeding
Number of subjects: 20323
Study 20413397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiogenic shock
Number of subjects: 20323
Study 20413397 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 20323
Study 20413397 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (among 30-day survivors)
Number of subjects: 20323
Study 20413397 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate (among 30-day survivors)
Number of subjects: 20323
Study 18701766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 18701766 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 15714213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 3310
Study 15714213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital discharge
Number of subjects: 3310
Study 15714213 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C deficiency
Number of subjects: 3310
Study 15714213 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid deficiency
Number of subjects: 3310
Study 15714213 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E deficiency
Number of subjects: 3310
Study 15714213 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(12) deficiency
Number of subjects: 3310
Study 15714213 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency
Number of subjects: 3310
Study 12093062 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy with additional multiantioxidant supplementation (Vitamin E and C, Allopurinol, N-acetylcysteine, and mannitol administered perioperatively)
Number of subjects: 42
Study 12093062 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 42
Study 10617256 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin suppositories (200 IU daily)
Number of subjects: 40
Study 10617256 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 40
Study 8803651 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 304
Study 8803651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 1442906 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery and presacral neurectomy
Number of subjects: 71
Study 1442906 — intervention group
Group type: COMPARATOR
Intervention: Conservative surgery alone
Number of subjects: 71
Study 6690191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg intravenous injection followed by 2 mg/h infusion)
Number of subjects: 10
Study 6690191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 10
Study 6690191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30537846 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg/hydrochlorothiazide 12.5 mg
Number of subjects: 12705
Study 30537846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 12705
Study 30537846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12705
Study 29632234 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg or 10 mg)
Number of subjects: 2832
Study 29632234 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg)
Number of subjects: 2832
Study 29632234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2832
Study 27722223 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (within 48 hours)
Number of subjects: 81
Study 27722223 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading (at 6 weeks)
Number of subjects: 81
Study 27722223 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading (at 3 months)
Number of subjects: 81
Study 24786925 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (ABA) treatment
Number of subjects: 652
Study 24786925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 22613690 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced early communication therapy by speech and language therapists (SL therapy), up to three contacts per week for up to 16 weeks
Number of subjects: 170
Study 22613690 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC) with a similar number of contacts by employed visitors
Number of subjects: 170
Study 20154405 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VG)
Number of subjects: 32
Study 20154405 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch (NG)
Number of subjects: 32
Study 18804227 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial azoospermic reading (pre-centrifugation)
Number of subjects: 3205
Study 16172865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry chamber dives
Number of subjects: 33
Study 16172865 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet chamber dives
Number of subjects: 33
Study 16172865 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 33
Study 12057861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) on days 1 and 8 plus carboplatin 300 mg/m(2) on day 1 (arm B)
Number of subjects: 198
Study 12057861 — intervention group
Group type: COMPARATOR
Intervention: cisplatin (CDDP) 70 mg/m(2) on day 1 plus vinblastine (VLB) 6 mg/m(2) on days 1 and 8 (arm A)
Number of subjects: 198
Study 10048518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar nerve block with mepivacaine HCI injection
Number of subjects: 21
Study 10048518 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve block with mepivacaine HCI injection
Number of subjects: 21
Study 10048518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ulnar and median nerve block
Number of subjects: 21
Study 10048518 — intervention group
Group type: COMPARATOR
Intervention: Preinjection strength
Number of subjects: 21
Study 10048518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar nerve block
Number of subjects: 21
Study 10048518 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve block
Number of subjects: 21
Study 7734353 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 234
Study 7734353 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 234
Study 7734353 — intervention group
Group type: EXPERIMENTAL
Intervention: b3a2 transcript subgroup with presenting white-cell count < 100 x 10(9)/l
Number of subjects: 234
Study 7734353 — intervention group
Group type: EXPERIMENTAL
Intervention: b2a2 transcripts
Number of subjects: 234
Study 7734353 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic breakpoint site or BCR/ABL RNA transcript
Number of subjects: 234
Study 7734353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic response
Number of subjects: 234
Study 1889319 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2
Number of subjects: 18
Study 1889319 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight Dextran
Number of subjects: 18
Study 6689424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic combination chemotherapy of mustine, vinblastine, prednisolone, and procarbazine (MVPP)
Number of subjects: 60
Study 6689424 — intervention group
Group type: COMPARATOR
Intervention: Total nodal irradiation (TNI)
Number of subjects: 60
Study 30635072 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assistance to quit smoking (including psychological and psychoeducational support, and pharmacological treatment advice if required) for 12 months
Number of subjects: 510
Study 30635072 — intervention group
Group type: COMPARATOR
Intervention: Brief advice after discharge
Number of subjects: 510
Study 30635072 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assistance to quit smoking
Number of subjects: 510
Study 29795207 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhoea at admission
Number of subjects: 400
Study 29795207 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of appetite
Number of subjects: 400
Study 29795207 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected sepsis
Number of subjects: 400
Study 29795207 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin ulcers
Number of subjects: 400
Study 29795207 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest indrawing
Number of subjects: 400
Study 29795207 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation below 94%
Number of subjects: 400
Study 29795207 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed HIV infection
Number of subjects: 400
Study 27274715 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxxTOR® (MT)
Number of subjects: 18
Study 27274715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 18
Study 24810684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training program (8 weeks)
Number of subjects: 36
Study 24810684 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 36
Study 22227587 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 0
Study 22227587 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART use among IDUs
Number of subjects: 0
Study 22227587 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART delivery to IDUs
Number of subjects: 0
Study 19159075 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% epinephrine (10 ml)
Number of subjects: 370
Study 19159075 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, 10 ml)
Number of subjects: 370
Study 17673583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee replacement
Number of subjects: 174
Study 17673583 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing total knee replacement
Number of subjects: 174